| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.0072 | 0.9 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | -0.019 | 0.9 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |